Clinical rationale for thymic restoration in adult immunosenescence.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic, preclinical, and observational literature without systematic review methodology or new human data.
PubMed 42415124 · doi:10.1186/s12979-026-00584-6
What was done
This review synthesized mechanistic, preclinical, and observational human data (including transplant and HIV cohorts and radiographic thymic imaging studies) to evaluate the clinical rationale, potential target domains, and emerging therapeutic approaches for reversing age-related thymic involution and adult immunosenescence.
What was found
No quantitative findings or effect sizes were reported in the abstract. The review outlined higher-confidence clinical domains for intervention (cancer immunosurveillance, infection risk, vaccine response, and immune reconstitution) and high-plausibility domains (autoimmunity, herpesvirus control, HIV non-responders, and long COVID). It categorized translational approaches into hormonal modulation (sex steroid ablation, growth hormone/ghrelin), cytokines/growth factors (IL-7, IL-22, KGF/BMP4, FGF21), cell/tissue engineering, and intrathymic gene therapy (FOXN1, AIRE). The authors noted that robust clinical benefits have not yet been demonstrated in controlled human trials.
Why it matters
This paper maps the translational landscape for targeting thymic involution as a core mechanism of immune aging, delineating indications supported by observational data from those based purely on biological plausibility.
Limits
As a narrative review, it presents no original clinical data or systematic quantitative meta-analysis. The abstract explicitly notes that domain-specific clinical efficacy and robust human benefits remain unproven in controlled trials.